Replies to post #195200 on Vivos Inc (RDGL)

[CatfishHunter]

⭐ RADIOGEL vs. YNTRADOSE — Why RadioGel Is the Superior Technology

YntraDose (BetaGlue) and RadioGel (Vivos Inc., RDGL) are both injectable Y-90 intratumoral therapies — but the technologies are NOT the same. One leaves permanent materials in the body; the other does not.

🔴 1. YntraDose leaves permanent microspheres in the body
• YntraDose uses Y-90 microspheres embedded in a “bioglue.”
• Microspheres do NOT dissolve. They remain in the tissue forever after the radiation decays.
• Permanent implants can affect:
• Future surgeries
• Imaging
• Re-treatment
• Long-term tissue reaction

This is the same limitation seen in SIR-Spheres and other microsphere platforms.

🔵 2. RadioGel leaves no permanent foreign material
• RadioGel uses tiny Y-90 phosphate particles (<2 µm) inside a hydrogel that gels in the tumor, then fully biodegrades.
• After ~10 days, Y-90 is inert.
• After gel resorption, nothing remains.
• The treatment area returns to normal tissue structure.

This is a major long-term safety advantage.

🔴 3. Microspheres cluster — dose is uneven

Microspheres tend to form clumps, creating:
• Hot spots
• Cold (undertreated) zones
• Higher dependence on injection precision

🔵 4. RadioGel fills the entire tumor and gives a more uniform dose

The hydrogel flows through the tumor microstructure before it solidifies, resulting in:
• Smooth, even distribution of Y-90
• Better coverage
• Lower risk of undertreated sections

This is a fundamental engineering advantage.

🔴 5. Microsphere migration risk exists

If microspheres reach small vessels or if injection isn’t perfect, migration can occur.

🔵 6. RadioGel’s gel matrix locks particles in place

Once gelled, the Y-90 is physically immobilized.
Migration risk is much lower.

🔴 7. YntraDose is best for simple, uniform tumors

Irregular shapes are harder to fill with microspheres glued in a single cluster.

🔵 8. RadioGel adapts to ANY tumor geometry

Because the gel flows into:
• Septa
• Channels
• Lobular structures
• Irregular tumor pockets

It is far more versatile.

⭐ BOTTOM LINE FOR INVESTORS

RadioGel is ultimately the superior clinical platform because:
• No permanent material remains
• Lower migration risk
• Better tumor coverage
• More predictable dosimetry
• Biodegradable hydrogel
• Safe across multiple animal species (IsoPet program already proven in dogs, cats, horses, etc.)

YntraDose is an interesting microsphere-based concept, but RadioGel’s design is safer, cleaner, and more advanced for long-term human use.

[SC8]

Please, all the original Radiogel patents are long expired. There's nothing stopping anyone from making a Radiogel offset. But you already knew that.

It appears there are technical and/or regulatory advantages to using the already approved encapsulated Y90 in an injectable gel vs. freely dispersed Y90 approach Radiogel uses, as it's just a fact the former is progressing in expanded human trials while the latter is dead in the water.

So the technical approach is irrelevant now. After treatment a dead tumor is a dead tumor. YntraDose is progressing forward with a three year head start in human trials. Radiogel isn't progressing.

Good to see more bailing on this scam today before it goes sub penny